	Case 2:19-cv-00777-JAM-DB Docume	ent 1 Filed 05/02/19 Page 1 of 16
1 2 3 4	KILPATRICK TOWNSEND & STOCKTO Taylor J. Pfingst (State Bar No. 316516) Two Embarcadero Center, Suite 1900 San Francisco, California 94111 Telephone: (415) 576-0200 Facsimile: (415) 576-0300	N, LLP
5	Counsel for Plaintiff DoseLogix, LLC	
6		
7	UNITED STAT	TES DISTRICT COURT
8	EASTERN DIST	TRICT OF CALIFORNIA
9		
10	DoseLogix, LLC,	Case No. 19-cv-340
11	Plaintiff,	COMPLAINT FOR PATENT INFRINGEMENT
12	V.	DEMAND FOR JURY TRIAL
13	BiosRX, Inc.,	DEMAND FOR JUNI TRIAL
14	Defendant.	
15		
16	Plaintiff DoseLogix, LLC ("DoseLogix") files this Complaint against Defendant BiosRX,	
17	Inc. ("BiosRX") and alleges the following:	
18	NAT	URE OF SUIT
19	1. This is an action for damages	s and equitable relief arising under the patent laws of
20	the United States, Title 35, United States C	Code, including in particular, Sections 271, 281, 283,
21	284, and 285, as a result of BiosRX's acts	of infringement of U.S. Patent No. 10,086,146 (the
22	"'146 Patent'').	
23	ТН	E PARTIES
24	2. DoseLogix is a corporation	organized and existing under the laws of the State of
25	Georgia, and has a principle place of busin	ess at 300 Parkbrooke Place, Suite 140, Woodstock,
26	GA, 30189. DoseLogix is in the business of manufacturing and selling medical dosing applicators	
27	and dispensers (and related products), includ	ling, but not limited to, the DoseLogix Topi-CLICK®
28	Perl [™] Vaginal Dosing Kit. DoseLogix is the current assignee and owner of the '146 Patent, and	
	COMPLAINT CASE NO. 19-cv-340	-1-

Case 2:19-cv-00777-JAM-DB Document 1 Filed 05/02/19 Page 2 of 16

is entitled to enforce all rights arising therefrom, including the right to prevent infringement of the
 patent.

3 3. On information and belief, BiosRX is a corporation organized under the laws of 4 the State of California, with its principle place of business at 1300 E Bidwell Street, Suite 105, 5 Folsom, CA 95630. On information and belief, BiosRX is registered to do business in California, 6 and has a regular and established place of business at 1300 E Bidwell Street, Suite 105, Folsom, 7 CA 95630. BiosRX may be served through its registered agent for service of process, Maryam 8 Amiri, 1028 Elsworth Way, Folsom, CA 95630. On information and belief, BiosRX makes, uses, 9 offers for sale, sells, and/or imports medical dosing applicators and dispensers in the United 10 States, including the Gentle Dose® vaginal applicator and TICKER® Unlimited.

11

JURISDICTION AND VENUE

12 4. This Court has subject matter jurisdiction over the subject matter of this action
13 under 28 U.S.C. § 1331 and 1338(a).

14 5. This Court has personal jurisdiction over BiosRX because the Court's exercise of 15 jurisdiction over BiosRX comports with due process. This Court has both general and specific 16 jurisdiction over BiosRX. BiosRX has continuous corporate operations within California and this 17 District in particular, that are so substantial and of such a nature as to justify suit against it on all 18 causes of action. On information and belief, BiosRX's principal place of business at 1300 E 19 Bidwell Street, Suite 105, Folsom, CA 95630. BiosRX also has certain minimum contacts with 20 California, and this District in particular, such that the maintenance of the suit does not offend 21 traditional notions of fair play and substantial justice. On information and belief, BiosRX is 22 registered to do business in California, has a regular and established place of business at 1300 E 23 Bidwell Street, Suite 105, Folsom, CA 95630, and has a registered agent for service of process in 24 California. As such, BiosRX's contacts with California, and this District in particular, are so 25 constant and pervasive as to render it essentially at home. Additionally, on information and belief, 26 BiosRX has purposefully directed activities at residents of the forum, the present patent infringement claims arises out of those activities, and assertion of personal jurisdiction over 27 28 BiosRX by this Court is reasonable and fair.

COMPLAINT CASE NO. Case 2:19-cv-00777-JAM-DB Document 1 Filed 05/02/19 Page 3 of 16

1 6. Venue is proper in this District pursuant to 28 U.S.C. § 1400(b) because BiosRX 2 resides in this District and BiosRX has a regular and established place of business in this District, 3 at 1300 E Bidwell Street, Suite 105, Folsom, CA 95630, and has committed acts of infringement 4 in this District. 5 **GENERAL ALLEGATIONS** 6 7. On October 2, 2018, the United States Patent and Trademark Office duly and 7 legally issued the '146 Patent. The '146 Patent is entitled "Flowable Composition Applicator." A 8 true and correct copy of the '146 Patent is attached to this Complaint as Exhibit A. 9 8. BiosRX makes, uses, offers to sell, and sells within the United States, and imports 10 into the United States, medical dosing applicators and dispensers, such as the Gentle Dose® 11 vaginal applicator and TICKER® Unlimited. See Exhibits B-C. 12 **Dosing Segment** Volume Plunger Barrel Tip 13 Grip Area Plunger Tip Markings Cap (anti-roll) (outlet) 14 15 16 Barrel (calibrated) 17 18 19 Learn How to UseTICKER Unlimited and Gentle Dose vaginal applicator 20 Julimited AGINAL APPLICATOR 21 22 23 24 25 26 27 MORE VIDEOS 28 -10 0:44 / 1:26 📼 🂠 YouTul

Case 2:19-cv-00777-JAM-DB Document 1 Filed 05/02/19 Page 4 of 16

2


1

3

9. BiosRX's activities with respect to such medical dosing applicators and dispensers, including the Gentle Dose® vaginal applicator and TICKER® Unlimited, infringe one or more claims of the '146 Patent.


4 10. For example, BiosRX's Gentle Dose[®] vaginal applicator infringes at least claim 1 5 of the '146 Patent, which recites: "An applicator comprising: a tube comprising a receptacle end 6 and a connector end opposite from the receptacle end, wherein the tube defines a hollow core 7 having a core wall extending from the connector end to the receptacle end; and a plunger 8 comprising a tip, a flared end opposite from the tip, and a lip extending outwards from the 9 plunger, wherein the plunger is movable within the hollow core between a dispensed position, a 10 loaded position, and a filled position, wherein a distance between the tip and the connector end in 11 the loaded position is greater than a distance between the tip and the connector end in the 12 dispensed position and less than a distance between the tip and the connector end in the filled 13 position, wherein the plunger is in the loaded position prior to loading of a flowable composition 14 within the hollow core, and wherein the lip forms a seal with the core wall of the tube."

15 11. The BiosRX Gentle Dose® vaginal applicator comprises a tube comprising a
16 receptacle end and a connector end opposite from the receptacle end, wherein the tube defines a
17 hollow core having a core wall extending from the connector end to the receptacle end, as
18 illustrated below:




Case 2:19-cv-00777-JAM-DB Document 1 Filed 05/02/19 Page 5 of 16

12. The BiosRX Gentle Dose® vaginal applicator comprises a plunger comprising a tip, a flared end opposite from the tip, and a lip extending outwards from the plunger, wherein the lip forms a seal with the core wall of the tube, as illustrated below:




14 13. The plunger of the BiosRX's Gentle Dose® vaginal applicator is movable within 15 the hollow core between a dispensed position, a loaded position, and a filled position, wherein a 16 distance between the tip and the connector end in the loaded position is greater than a distance 17 between the tip and the connector end in the dispensed position and less than a distance between 18 the tip and the connector end in the filled position, as illustrated in part below:







19 core having a core wall extending from the receptacle end to the connector end; and a plunger 20 comprising a tip, a flared end opposite the tip, and an outer surface extending from the tip to the 21 flared end, wherein the plunger is movable within the hollow core between a dispensed position 22 and a filled position, wherein the plunger comprises at least two ribs extending outwardly from 23 the outer surface of the plunger between tip and the flared end that are spaced apart by a 24 predetermined distance, and wherein the tip of the plunger protrudes a predetermined distance 25 through the connector end of the tube and away from the connector end of the tube when the 26 plunger is in the dispensed position."

27 16. The BiosRX Gentle Dose® vaginal applicator comprises a tube comprising a
 28 receptacle end and a connector end opposite the receptacle end, wherein the tube defines a hollow









13 wall extending from the connector end to the receptacle end; and a plunger comprising a tip and a 14 flared end opposite the tip, wherein the plunger is movable within the hollow core between a 15 dispensed position, a loaded position, and a filled position, wherein a distance between the tip and 16 the connector end in the loaded position is greater than a distance between the tip and the 17 connector end in the dispensed position and less than a distance between the tip and the connector 18 end in the filled position; and an administering tool comprising a dispenser nozzle, wherein the 19 dispenser nozzle comprises a tip, and wherein the tip of the nozzle is receivable within the hollow 20 core at the connector end such that the plunger is moved from the dispensed position to the loaded 21 position prior to loading of a flowable composition within the hollow core." 22

22. The BiosRX Gentle Dose® vaginal applicator comprises a tube comprising a 23 receptacle end and a connector end opposite the receptacle end, wherein the tube defines a hollow 24 core having a core wall extending from the connector end to the receptacle end, as illustrated 25 below: 26

- 27
- 28





Case 2:19-cv-00777-JAM-DB Document 1 Filed 05/02/19 Page 12 of 16




TICKER® Unlimited infringes at least claim 8 of the '146 Patent, which recites: "The applicator 25 system of claim 7, wherein the tip of the plunger protrudes a predetermined distance through the 26 connector end of the tube and away from the connector end when the plunger is in the dispensed 27 position." 28

COMPLAINT CASE NO.


Case 2:19-cv-00777-JAM-DB Document 1 Filed 05/02/19 Page 13 of 16

28. The tip of the plunger of the BiosRX Gentle Dose® vaginal applicator protrudes a
 predetermined distance through the connector end of the tube and away from the connector end
 when the plunger is in the dispensed position, as illustrated below:



29. The system of BiosRX's Gentle Dose® vaginal applicator and BiosRX's
TICKER® Unlimited infringes at least claim 9 of the '146 Patent, which recites: "The applicator
system of claim 7, wherein the plunger comprises at least two ribs extending outwardly from an
outer surface of the plunger between the tip of the plunger and the flared end, and wherein the at
least two ribs are spaced apart by a predetermined distance."

30. The plunger of the BiosRX Gentle Dose® vaginal applicator comprises at least
two ribs extending outwardly from an outer surface of the plunger between the tip of the plunger
and the flared end, and wherein the at least two ribs are spaced apart by a predetermined distance,
as illustrated below:



Case 2:19-cv-00777-JAM-DB Document 1 Filed 05/02/19 Page 14 of 16

31. On information and belief, BiosRX has had knowledge of the '146 Patent prior to
 (and at least since) the filing of this Complaint. Despite such knowledge of the '146 Patent,
 BiosRX continued, and still continues today, to manufacture, use, offer for sale, sell in the United
 States (including in this District), and/or import into the United States, medical dosing applicators
 and dispensers, including the Gentle Dose® vaginal applicator and TICKER® Unlimited, that
 infringe one or more claims of the '146 Patent.

8 32. DoseLogix realleges, adopts, and incorporates by reference each of the foregoing
9 allegations as if fully set forth herein.

33. BiosRX has manufactured, used, offered for sale, sold within the United States
(including in this District), and/or imported into the United States, and continues to manufacture,
use, offer for sale, sell in the United States (including in this District), and/or import into the
United States, medical dosing applicators and dispensers, including the Gentle Dose® vaginal
applicator and TICKER® Unlimited, that incorporate each and every element of one or more of
the claims of the '146 Patent and therefore are covered by the '146 Patent ("the Accused
Products").

34. BiosRX has been infringing and continues to infringe the '146 Patent, either
literally or under the doctrine of equivalents, by making, using, selling, offering for sale in the
United States, and/or importing into the United States the Accused Products, such as the Gentle
Dose® vaginal applicator and TICKER® Unlimited, that embody each element of at least one of
the claims of the '146 Patent and will continue to do so unless enjoined by this Court.

22 35. BiosRX also indirectly infringes the '146 Patent within the United States by 23 inducement under 35 U.S.C. § 271(b). Since learning of the '146 Patent and by failing to cease offering the Accused Products, BiosRX has knowingly and intentionally induced, and continues 24 25 knowingly and intentionally to induce, others in this District and throughout the United States to 26 directly infringe one or more claims of the '146 Patent. BiosRX does so, *inter alia*, by advertising 27 and promoting the use of the Accused Products on BiosRX's website, including, but not limited, 28 through one more instructional videos, such as the video available or at -14-COMPLAINT

CASE NO.

Case 2:19-cv-00777-JAM-DB Document 1 Filed 05/02/19 Page 15 of 16

1	https://www.youtube.com/watch?v=ZcaenGCzguI&feature=youtu.be. See Exhibit B-C.	
2	36. BiosRX also indirectly infringes the '146 Patent by contributing to the direct	
3	infringement of end users under 35 U.S.C. § 271(c) by providing the Accused Products, which, as	
4	evidenced by BiosRX's own marketing materials and instructional videos, are specially made for	
5	use in a manner infringing one or more claims of the '146 Patent, and are not staple articles of	
6	commerce for substantial non-infringing uses. See Exhibits B-C.	
7	37. DoseLogix has been damaged by BiosRX's infringement of the '146 Patent and	
8	will suffer additional irreparable damage and impairment of the value of its patent rights unless	
9	BiosRX is enjoined from continuing to infringe.	
10	38. DoseLogix has suffered damages as a result of BiosRX's infringement of the '146	
11	Patent, including in the form of lost profits, lost sales, and/or lost opportunities. DoseLogix is	
12	entitled to recover damages to compensate it for BiosRX's infringing activities in an amount to be	
13	determined at trial, but in no event less than a reasonable royalty.	
14	39. BiosRX's infringement has been and continues to be egregious and willful, with	
15	knowledge of the existence of the '146 Patent, such that DoseLogix is entitled to recover its	
16	attorneys' fees and other expenses of litigation pursuant to 35 U.S.C. § 285.	
17	JURY DEMAND	
18	In accordance with Rule 38(b) of the Federal Rules of Civil Procedure, DoseLogix	
19	requests a trial by jury on any issue in this action triable by right before a jury.	
20	PRAYER FOR RELIEF	
21	WHEREFORE, DoseLogix respectfully requests that the Court:	
22	(a) Enter judgment that BiosRX has infringed the '146 Patent, and that such	
23	infringement has been willful;	
24	(b) Preliminarily and permanently enjoin BiosRX from infringing the '146 Patent,	
25	pursuant to 35 U.S.C. § 283, or grant such other equitable relief the Court determines is	
26	warranted;	
27	(c) Award DoseLogix damages in an amount to be proven at trial because of the	
28	injury suffered by reason of BiosRX's infringement of the '146 Patent, including but not limited	
	COMPLAINT -15-	

	Case 2:19-cv-00777-JAM-DB Document 1 Filed 05/02/19 Page 16 of 16	
1	to pre-issuance damages;	
2	(d) Increase the damages awarded to DoseLogix up to three times the amount found to	
3	be DoseLogix's actual damages, as authorized by 35 U.S.C. § 284;	
4	(e) Award DoseLogix its attorney's fees and other expenses of litigation pursuant to	
5	35 U.S.C. § 285;	
6	(f) Award DoseLogix prejudgment interest and costs pursuant to 35 U.S.C. § 284; and	
7	(g) Award DoseLogix such other and further relief as the Court deems proper.	
8	DATED: May 2, 2019 Respectfully submitted,	
9	KILPATRICK TOWNSEND & STOCKTON LLP	
10		
11	By: <u>/s/Taylor J. Pfingst</u> TAYLOR J. PFINGST	
12	Counsel for Plaintiff DoseLogix, LLC	
13	Counsel jor T lunnijj DoseLogix, ELC	
14		
15		
16		
17		
18		
19 20		
20 21		
21 22		
22		
23 24		
24 25		
23 26		
20		
28		
	COMPLAINT -16- CASE NO.	